Related Experiment Video
Updated: Aug 21, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Mortality in sickle cell patients on hydroxyurea therapy
Sule M Bakanay1, Erin Dainer, Betsy Clair
1Sickle Cell Center, Department of Medicine, Office of Biostatistics and Bioinformatics, Medical College of Georgia, Augusta 30912, USA.
Abstract:
The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. Nevertheless, many patients still die of complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell-related causes). Acute chest syndrome (ACS) was the most common (35%) cause of death. Deceased and surviving patients did not differ significantly in average HU dose, baseline fetal hemoglobin (Hb F), or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic, and more likely to have BAN or CAM haplotypes. They also had significantly higher serum blood-urea-nitrogen (BUN) and creatinine levels. Sickle cell patients who die while on HU therapy may represent a subgroup of older patients, possibly with more severe disease and more severe organ damage. Such patients need early identification and prompt HU institution.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Lifecycle of Erythrocytes
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
Heart Failure VI: Adjunct Therapies
Hemodialysis III: Nursing Management
Multipotency of Hematopoietic Stem Cells
